PharVision Advisers’s Embecta EMBC Stock Holding History

PharVision Advisers’s Portfolio EMBC Stock Details EMBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,877	Closed	-$140K	–	82
2026 Q1	$140K	Buy	15,877 +4,642	+41%	+$48.4K	1.42%	16
2025 Q4	$133K	Buy	+11,235	New	+$148K	0.07%	630

Other funds holding EMBC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

YAM

Yacktman Asset Management Austin, Texas $8.09B AUM 19.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Brigade Capital Management New York $534M AUM 44.37% 1-Year Est. Return

PharVision Advisers's EMBC Position: Q2 2026 in Review

PharVision Advisers sold out of Embecta (EMBC) in Q2 2026, closing a stake of 15,877 shares — an estimated $140K sold.

PharVision Advisers first reported a position in EMBC in Q4 2025 and held it in 2 quarters. The position peaked at $140K in Q1 2026. 322 funds tracked by Wall St. Rank hold EMBC as of Q2 2026.

PharVision Advisers reported no remaining Embecta position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 15,877 Embecta shares in Q2 2026, an estimated $140K.
PharVision Advisers first reported a position in Embecta in Q4 2025 and held it in 2 quarters.
PharVision Advisers's Embecta position peaked at $140K in Q1 2026.
322 funds tracked by Wall St. Rank held Embecta as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.